Intersect ENT’s Acquisition Of Fiagon AG


Morrison & Foerster LLP advised the shareholders of Fiagon AG Medical Technologies on the deal.

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, announced it has entered into an agreement to acquire Fiagon AG Medical Technologies, a leader in electromagnetic surgical navigation solutions, for €60 million in cash. Under the terms of the transaction, Intersect ENT will make an initial €15 million payment at the time of the closing and €15 million annual payments for the subsequent three years.

Over the past 10 years, Fiagon, along with world-renowned physicians, changed the standard of ENT navigation with its easy-to-use electromagnetic-based technology. This unique technology is also currently used in oral and maxillofacial surgery, neurosurgery, and spine surgery outside of the U.S., mainly in Europe and Asia.

The MoFo deal team advising the shareholders of Fiagon is led by Berlin managing partner and head of the firm’s European Corporate and M&A groups Dirk Besse (Picture), together with Berlin partners Wolfgang Schoenig (Technology Transactions/Intellectual Property), Jens-Uwe Hinder (Tax), Hanno Timner (Employment/Labor), and Angela Kerek (Finance).

Involved fees earner: Dirk Besse – Morrison Foerster; Jens-Uwe Hinder – Morrison Foerster; Angela Kerek – Morrison Foerster; Wolfgang Schönig – Morrison Foerster; Hanno Timner – Morrison Foerster;

Law Firms: Morrison Foerster;

Clients: Fiagon AG Medical Technologies;